FXN and Friedreich ataxia: As the phenotype of FRDA in subjects with point mutations altering frataxin production or stability is almost identical with those with GAA repeats, the clinical syndrome largely if not entirely reflects the loss of frataxin protein rather than the effects on frataxin mRNA levels.